Eruptive Nevi Associated with Estrogen-progestin Therapy: A Unique Case Report
Z. Loubaris *
Department of Dermatology, Mohamed V University of Rabat, Ibn Sina University hospital, Morocco.
R. Moumna
Department of Dermatology, Mohamed V University of Rabat, Ibn Sina University hospital, Morocco.
L. Benzekri
Department of Dermatology, Mohamed V University of Rabat, Ibn Sina University hospital, Morocco.
M. Meziane
Department of Dermatology, Mohamed V University of Rabat, Ibn Sina University hospital, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Background: Eruptive nevi represents a quite rare dermatological phenomenon with a sudden onset of multiple melanocytic nevi over a short period of time.
Objective: To describe a unique case of eruptive nevi developed along with estrogen-progestin therapy; and to consider the clinical significance of this case and possible hormonal aetiology.
Methods: This is a single case report detailing the rapid development of around fifty new melanocytic nevi during the course of three months in an 18-year-old girl, concurrent with the commencement of estrogen-progestin therapy. The nevi were evaluated clinically and dermoscopically, and laboratory investigations were undertaken to rule out systemic illness or malignancy.
Results: The nevi had symmetrical distribution, uniform pigmentation, and benign dermatoscopic features. There were no other signs of either systemic illness or malignancy. It became noticeable after discontinuation of estrogen-progestin therapy that no new moles appeared within the six-month follow-up period.
Limitations: This is a single-case study; therefore, generalizability is limited. There remain some speculative issues in the pathophysiological connection between estrogen-progestin treatment and nevogenesis.
Conclusion: This case report highlights the potentiality of estrogen-progestin treatment to cause eruptive nevi and urges consideration of all such hormonal factors by clinicians in similar cases.
Keywords: Eruptive nevi, estrogen-progestin therapy, melanocytic proliferation, hormonal factors, cutaneous manifestations